Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial. (4th August 2022)

• Record Type: Journal Article
• Authors: Huygens, Sammy; Hofsink, Quincy; Nijhof, Inger S; Goorhuis, Abraham; Kater, Arnon P; te Boekhorst, Peter A W; Swaneveld, Francis; Novotný, Věra M J; Bogers, Susanne; Welkers, Matthijs R A; Papageorgiou, Grigorios; Rijnders, Bart J; Heijmans, Jarom
• Is Part Of: Journal of infectious diseases. Volume 227:Number 2(2023)
• Page Start: 206
• Page End: 210
• Publication Date: 2022-08-04
• Subjects: anti-SARS-CoV-2 hyperimmune globulin -- B-cell dysfunction -- COVID-19 -- plasma-derived antibody therapy -- severely immunocompromised state; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiac334
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Background: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. Methods: Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. Results: Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group ( P = .015, Fisher's exact test). Conclusions: Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available. Abstract : Anti-SARS-CoV-2 hyperimmune globulin (COVIG) could be a therapy for severely immunocompromised, hospitalized, COVID-19 patients. We performed a randomized, placebo-controlled trial in which a single intravenous infusion with 15 grams of COVIG significantly reduced the progression to severe COVID-19.